Tech quarterlies: ZipCo targets US expansion
Ovanti reported a milestone quarter with former Zip Co US CFO Simon Keast appointed as its new CEO and mandate to launch BNPL offering in US.
Stockhead
ASX rebounds as Trump delays tariffs
ASX bounces back on Trump’s tariff delay, tech stocks shine, but Seek’s $42m deal crashes and Xref tanks 22pc.
Wellnex secures TGA approval
Wellnex obtains market authorisation with the Therapeutic Goods Administration for Liquid Paracetamol plus Caffeine Soft Gel.
Takeover whispers add lift to cashed-up PDI
Gold hunter PDI climbs on $69.2m placement amid reports of the company’s large M&A appeal.
More Stories
Optiscan kicks off GI study in Germany
Optiscan completes first gastrointestinal (GI) flexible prototype to collect images from the GI tract and activates GI study at major German university.
OZM’s high-grade gold hits excites punters
OzAurum’s high-grade drill hits at the Mulgabbie North project have identified a new zone that outlines its potential to host significant mineralisation.
Caprice targets maiden gold resource
Caprice has recommenced drilling at its promising Island gold project, which hosts historic workings just 12km from Ramelius’ Cue mine.
OZM hits high-grade gold at Mulgabbie North
Drill hits of up to 4m at 14.17g/t gold have led to OzAurum identifying a new high-grade target at its Mulgabbie North gold project.
Cash backs Indiana’s golden opportunity
Indiana Resources is a rare junior with massive cash backing, but its South Australian gold prospects could be the real value driver.
Paradigm eyes $110m raise with loyalty offer
Paradigm Biopharmaceuticals has launched loyalty options and piggyback options offers which could potentially raise more than $110 million.
How major commodities fared in 2024
Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a tumultuous 2024.
Shares dive on Trump’s tariffs
The ASX has crashed today on Trump’s tariffs. Meanwhile oil has risen, crypto has absolutely face-planted and Novonix is up on an anti-China dumping win.
PAR picks Advanced Clinical for key trial
Paradigm Biopharmaceuticals has selected Advanced Clinical as the preferred clinical research organisation for the phase III trial for PARA_OA_012.
AAR moves to acquire MXR
Astral Resources’ takeover offer values Maximus Resources at ~$31m and will provide more flexible future development of existing gold resources.
Original URL: https://www.adelaidenow.com.au/business/stockhead/page/3